Management of NSAID-induced gastropathy: An economic decision analysis

Clinical Therapeutics

Volumn 19, Issue 6, 1997, Pages 1496-1509

  Goldstein, Jay L ^a   Larson, Leanne R ^b   Yamashita, Beverly D ^b   Boyd, Mark S ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ClinTrials Ovation   (United States)

Author keywords

Cost benefit analysis; Decision analysis; Diclofenac; Duodenal ulcer; Gastric ulcer; Misoprostol; NSAID induced gastropathy

Indexed keywords

DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT;

COST BENEFIT ANALYSIS; COST CONTROL; DECISION MAKING; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; REVIEW; STOMACH DISEASE; TREATMENT OUTCOME;

EID: 0031431552     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80021-5     Document Type: Note

References (45)

1. Gabriel SE, Fehring RA. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States 1866-1990. J Clin Epidemiol. 1992;45:1041-1044.
2. Miller LG, Prichard JG. Current issues in NSAID therapy. Prim Care. 1990;17: 589-601.
3. Cummings DM, Amadio P Jr. A review of selected newer nonsteroidal anti-inflammatory drugs. Am Fam Phys. 1994;49: 1197-1202.
4. Hirschowitz BI. Nonsteroidal anti-inflammatory drugs and the gut. South Med J. 1996;89:259-263.
5. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci. 1995;40:1125-1131.
6. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141:539-545.
7. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies. Am J Med. 1994;96:274-281.
8. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996;156:1530-1536.
9. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med. 1996;101(Suppl 1A): 25S-32S.
10. PDA's NSAID class labeling estimate of 4-6% GI adverse reaction annually is not valid, PMA maintains: PMA proposes industry-consensus NSAID label warning. FDA Reports. November 30, 1987;30:8-9.
11. Butt JH, Barthel JS, Moore RA. Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1988;84:5-14.
12. Fries J. Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data. Scand J Rheumatol. 1996;25(Suppl 102):3-8.
13. Kendall BJ, Peura DA. NSAID-associated gastrointestinal damage and the elderly. Pract Gastroenterol. 1993;17:13-29.
14. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol. 1992;(Suppl 92):21-24.
15. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241-249.
16. Bianchi Porro G, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Am J Gastroenterol. 1997; 92:663-667.
17. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91:223-227.
18. Data on file. G.D. Searle & Co., Skokie, Illinois. Drug Utilization Evaluation of Michigan Medicaid claims database (12/1/94-11/30/95). Analysis Tool Rational MED™, PharMark Corp., 1995.
19. Koch M, Dezi A, Ferrario F, et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996;156:2321-2332.
20. Ehsanullah RSB, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. BMJ. 1988;297:1017-1021.
21. Robinson MG, Griffin JW, Bowers J, et al. Effects of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 1989;34:424-428.
22. Champion GD, Feng PH, Azuma T, et al. NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus. Drugs. 1997;53:6-19.
23. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDS. Ann Intern Med. 1993;119: 257-262.
24. 2-antagonists in an ambulatory elderly population. J Geriatr Drug Ther. 1993;7:73-83.
25. Data on file. G.D. Searle & Co., Skokie, Illinois. NSAID-Induced Gastropathy. Drug Utilization Analysis - Integrated Pharmaceutical Services Foundation. Prescription database queried from 1/1/96 to 4/30/96.
26. Graham DY, Stromatt SC, Jaszewski R. Prevention of duodenal ulcers in arthritics who are chronic NSAID users: A multicenter trial of the role of misoprostol. Gastroenterology. 1991;100:A75. Abstract.
27. Bocanegra TS, Weaver AL, Tindall EA, et al. Efficacy and gastrointestinal safety of diclofenac/misoprostol compared with diclofenac in osteoarthritis of the knee or hip: A randomized placebo controlled trial. J Rheumatol. In press.
28. Verdickt V, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol. 1992;21:85-91.
29. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine in the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. NEJM. 1996;334:1435-1439.
30. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2:1277-1280.
31. Study 041. Data on file. G.D. Searle & Co., Skokie, Illinois.
32. Raskin J, White R, Jaszewski R. Double-blind comparative study of the efficacy and safety of misoprostol and ranitidine in the prevention of NSAID-induced gastric ulcers and upper gastrointestinal symptoms: Preliminary findings. Digestion. 1991;49(Suppl):50-51.
33. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of non-steroidal anti-inflammatory drug-induced gastric ulcer. Ann Intern Med. 1991;115:195-200.
34. Kong SX. Prevalence and costs of gastrointestinal hemorrhage: Estimates from a claims database. Am J Managed Care. In press.
35. Zeidler H. Epidemiology and economics of NSAID-induced gastropathy. Scand J Rheumatol. 1992;(Suppl 92):3-8.
36. Health services resources and utilization. In: Source Book of Health Insurance Data. Washington, DC: Health Insurance Association of America; 1995:113-150.
37. Pearson SP, Kelberman I. Gastrointestinal effects of NSAIDs. Difficulties in detection and management. Postgrad Med J. 1996;100:131-143.
38. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:2061-2065.
39. Geis GS, Stead H, Bertil Wallemark C, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol. 1991;18(Suppl 28):11-14.
40. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med. 1991;91:213-222.
41. Sclar DA, Robinson LM, Maheu A, Skaer TL. Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada. J Int Med Res. 1995;23:439-448.
42. Mosby's Complete Drug Reference Physicians GenRx. St. Louis: Mosby-Year Book, Inc; 1997:653,1581,1820.
43. Hillman AL. Economic analysis of alternative treatments for persistent gastrooesophageal reflux disease. Scand J Gastroenterol. 1994;29(Suppl 201):98-102.
44. Greenberg PD, Koch J, Cello JP. Clinical utility and cost effectiveness of Helicobacter pylori testing for patients with duodenal and gastric ulcers. Am J Gastroenterol. 1996;91:228-232.
45. Elixhauser A, McCarthy E. Clinical Classifications for Health Policy Research, Version 2: Hospital Inpatient Statistics. AHCPR Publication No. 96-0017. Healthcare Cost and Utilization Project (HCUP-3) Research Note I. Rockville, MD: Agency for Health Care Policy and Research; 1996:26-27.